title: Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion.
abstract: OBJECTIVE
  We examined the importance of prolonged inflation time for optimal sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) expansion.
  
  
  METHODS
  Eighty-one de novo lesions deployed single SES or PES between April 2007 and March 2008 were divided into four groups; group 1: 21 SES deployed at 20 atm x 60 sec, group 2: 20 SES deployed with 2-step inflation at 20 atm x 60 sec following 20 atm x 20 sec, group 3: 20 PES deployed same as group 1, group 4: 20 PES deployed same as group 2. The minimal lumen diameter (MLD) and stent expansion ratio (SER; stent cross- sectional area at lesion/balloon cross-sectional area which was calculated according to the compliance chart at the same atmosphere as stent deployment) were compared between group 1 and group 2 in SES, between group 3 and group 4 in PES.
  
  
  RESULTS
  The MLD of post 60 sec was significantly higher than that of post 20 sec (2.84 +/- 0.28 mm in group 1, 2.76 +/- 0.33 mm in group 2 vs. 2.54 +/- 0.33 mm in group 2; P = 0.003, 0.045, respectively and 2.94 +/- 0.28 mm in group 3, 3.00 +/- 0.34 mm in group 4 vs. 2.69 +/- 0.35 mm in group 4; P = 0.022, 0.007, respectively). The SER of post 60 sec was significantly higher than that of post 20 sec (79.3% +/- 8.5% in group 1, 80.8% +/- 7.8% in group 2 vs. 71.1% +/- 10.2% in group 2; P = 0.014, 0.011, respectively and 81.1% +/- 7.9% in group 3, 84.3% +/- 9.9% in group 4 vs. 72.6% +/- 10.5% in group 4, P = 0.011, 0.001, respectively).
  
  
  CONCLUSIONS
  The prolonged delivery inflation for 60 sec may result in a more optimal stent expansion. It is therefore considered to be a useful method for deploying drug-eluting stent.
authors.affiliation: Cardiovascular Center, Shin-Koga Hospital, Tenjin-cho, Kurume, Japan. to-kawasaki@mug.biglobe.ne.jp
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Koga
authors.forename: Takeshi
authors.initials: T
authors.lastname: Serikawa
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Orita
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Ikeda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mito
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Gotou
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Shintani
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tanaka
authors.forename: Hidenori
authors.initials: H
authors.lastname: Tanaka
authors.forename: Takaya
authors.initials: T
authors.lastname: Fukuyama
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Koga
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel; D020123:Sirolimus